Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Blinatumomab (Blincyto®) is recommended as an option for use within NHS Wales as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. |
|||
|
|||
Medicine details |
|||
| Medicine name | blinatumomab (Blincyto®) | ||
| Formulation | 38.5 micrograms powder for concentrate and solution for solution for infusion | ||
| Reference number | 3769 | ||
| Indication | Monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation |
||
| Company | Amgen Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0519 | ||
| NMG meeting date | 06/03/2019 | ||
| AWMSG meeting date | 10/04/2019 | ||
| Date of issue | 12/04/2019 | ||
| Date of last review | June 2022 | ||
| Commercial arrangement | PAS | ||
| Further information Technologies recommended by NICE that include a commercial arrangement (excel) |
|||